These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34181360)

  • 1. A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Liranso T; Adewole T; Fry N; Hull JT; Busse GD; Chowdhry F; Cutler AJ; Jones NJ; Findling RL; Schwabe S
    J Clin Psychopharmacol; 2021 Jul-Aug 01; 41(4):370-380. PubMed ID: 34181360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children.
    Nasser A; Liranso T; Adewole T; Fry N; Hull JT; Chowdhry F; Busse GD; Cutler AJ; Jones NJ; Findling RL; Schwabe S
    Clin Ther; 2020 Aug; 42(8):1452-1466. PubMed ID: 32723670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
    CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial.
    Nasser A; Liranso T; Adewole T; Fry N; Hull JT; Chowdhry F; Busse GD; Melyan Z; Cutler AJ; Findling RL; Schwabe S
    Clin Ther; 2021 Apr; 43(4):684-700. PubMed ID: 33750646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD.
    Nasser A; Liranso T; Adewole T; Fry N; Hull JT; Chowdhry F; Busse GD; Melyan Z; Cutler AJ; Findling RL; Schwabe S
    Psychopharmacol Bull; 2021 Mar; 51(2):43-64. PubMed ID: 34092822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Kosheleff AR; Hull JT; Liranso T; Qin P; Busse GD; O'Neal W; Fava M; Faraone SV; Rubin J
    J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):214-226. PubMed ID: 33600233
    [No Abstract]   [Full Text] [Related]  

  • 7. Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials.
    Faraone SV; Gomeni R; Hull JT; Busse GD; Melyan Z; Rubin J; Nasser A
    Paediatr Drugs; 2021 Nov; 23(6):583-589. PubMed ID: 34523063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response of peer relations and social activities to treatment with viloxazine extended-release capsules (Qelbree
    Faraone SV; Gomeni R; Hull JT; Busse GD; Lujan B; Rubin J; Nasser A
    Brain Behav; 2023 Apr; 13(4):e2910. PubMed ID: 36847750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder.
    Faraone SV; Gomeni R; Hull JT; Busse GD; Melyan Z; Rubin J; Nasser A
    Eur Child Adolesc Psychiatry; 2023 Mar; 32(3):491-499. PubMed ID: 34581911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Wilens TE; Robertson B; Sikirica V; Harper L; Young JL; Bloomfield R; Lyne A; Rynkowski G; Cutler AJ
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release.
    Schein J; Cloutier M; Gauthier-Loiselle M; Catillon M; Xu C; Chan D; Childress A
    J Manag Care Spec Pharm; 2024 Jun; 30(6):528-540. PubMed ID: 38824626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials.
    Nasser A; Hull JT; Liranso T; Busse GD; Melyan Z; Childress AC; A Lopez F; Rubin J
    Neuropsychiatr Dis Treat; 2021; 17():1751-1762. PubMed ID: 34113106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder.
    Jain R; Segal S; Kollins SH; Khayrallah M
    J Am Acad Child Adolesc Psychiatry; 2011 Feb; 50(2):171-9. PubMed ID: 21241954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder.
    Price MZ; Price RL
    CNS Drugs; 2023 Jul; 37(7):655-660. PubMed ID: 37430151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Guanfacine Extended-Release in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled Study.
    Iwanami A; Saito K; Fujiwara M; Okutsu D; Ichikawa H
    J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32297719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of placebo response in the efficacy outcome assessment in viloxazine extended-release pivotal trials in paediatric subjects with attention-deficit/hyperactivity disorder.
    Nasser A; Gomeni R; Wang Z; Hull JT; Busse GD; Melyan Z; Fava M; O'Neal W; Rubin J
    Br J Clin Pharmacol; 2022 Nov; 88(11):4828-4838. PubMed ID: 35588245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.